H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Amarin (NASDAQ:AMRN) Corporation Plc on Friday, setting a price target of $10, which is approximately 43.88% above the present share price of $6.95.
Fein expects Amarin Corporation Plc to post earnings per share (EPS) of -$0.02 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Amarin, with an average price target of $10.38.
The analysts price targets range from a high of $19 to a low of $6.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $156.5 million and a net profit of -$6.94 million. The company's market cap is $2.95 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.2% and a 54.20% success rate.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.